首页> 外文期刊>European journal of clinical pharmacology >An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice.
【24h】

An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice.

机译:骨转换的生物标志物及其在生物医学研究和临床实践中的实用性的更新。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Maintenance of the structural and functional integrity of the skeleton is a critical function of a continuous remodeling driven by highly associated processes of bone resorption and synthetic activities driven by osteoclasts and osteoblasts, respectively. Acceleration of bone turnover, accompanied with a disruption of the coupling between these cellular activities, plays an established role in the pathogenesis of metabolic bone diseases, such as osteoporosis. During the past decades, major efforts have been dedicated to the development and clinical assessment of biochemical markers that can reflect the rate of bone turnover. Numerous studies have provided evidence that serum levels or urinary excretion of these biomarkers correlate with the rate of bone loss and fracture risk, proving them as useful tools for improving identification of high-risk patients. OBJECTIVE: The aim of the present review is to give an update on biomarkers of bone turnover and give an overview of their applications in epidemiological and clinical research. DISCUSSION: Special attention is given to their utility in clinical trials testing the efficacy of drugs for the treatment of osteoporosis and how they supplement bone mass measurements. Recent evidence suggests that biochemical markers may provide information on bone age that may have indirectly relates to bone quality; the latter is receiving increasing attention. A more targeted use of biomarkers could further optimize identification of high-risk patients, the process of drug discovery, and monitoring of the efficacy of osteoporosis treatment in clinical settings.
机译:背景:骨骼结构和功能完整性的维持是连续重塑的关键功能,该重塑分别由破骨细胞和成骨细胞驱动的高度相关的骨骼吸收过程和合成活动驱动。骨转换的加速,伴随着这些细胞活性之间的耦合的破坏,在代谢性骨疾病如骨质疏松症的发病机理中起着确定的作用。在过去的几十年中,已经做出了巨大的努力来开发和反映能够反映骨转换速率的生化标志物的临床评估。大量研究提供了证据,这些生物标志物的血清水平或尿液排泄与骨质流失和骨折风险相关,证明它们是改善高危患者识别的有用工具。目的:本综述的目的是提供有关骨转换的生物标志物的最新信息,并概述其在流行病学和临床研究中的应用。讨论:在临床试验中特别注意它们的用途,这些试验用于测试药物治疗骨质疏松症的功效以及它们如何补充骨量测量。最近的证据表明,生化标记物可能提供有关骨龄的信息,而这些信息可能与骨质量间接相关。后者正受到越来越多的关注。生物标志物的更有针对性的使用可以进一步优化高危患者的识别,药物发现的过程以及在临床环境中监测骨质疏松症治疗的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号